June 22, 2018
Via: Mass DeviceThe FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes. The device is the first CGM system to feature an implantable sensor that can be worn for up to […]
July 9, 2024
June 25, 2024